Brainstorm granted patents for allogeneic exosome platform-product in neurological disorder treatments

New york , dec. 26, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for nurown® and nurown-exosomes. the european patent office granted patent no.
BCLI Ratings Summary
BCLI Quant Ranking